StockMarketWire.com - Tiziana Life Sciences has entered into an exclusive license agreement with TTFactor S.r.l., acting on behalf of the FIRC Institute for Molecular Oncology, and the European Institute of Oncology, covering the use of twenty defined stem cell markers for patient stratification in breast cancer.
The TOP 20 model is a gene expression signature capable of predicting disease aggressiveness and prognosis in breast cancer patients.
It is different from all other signatures available today because it is derived from cancer stem cells and therefore it predicts cancer behaviour based on its stem cell content.
The TOP 20 genes have been defined based on published expression profiles of breast stem cells, and further selected based on their levels of expression and likelihood of reduction into practice for patient stratification in breast cancer.
The inventor of the TOP 20 model, Professor Pier Paolo Di Fiore, a physician and specialist in molecular oncology and cell biology, is a consultant to Tiziana and a member of Tiziana's Scientific Advisory Board.
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.